July 10, 2023
The Food and Drug Administration granted traditional (full) approval to Leqembi, the Alzheimer’s
treatment jointly developed by Biogen and Eisai, on July 6th. In early June, external advisors to the FDA unanimously recommended Leqembi for full approval.